R 116010

Drug Profile

R 116010

Latest Information Update: 11 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Class Antineoplastics; Benzothiazoles; Imidazoles
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; Retinoic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 31 Jul 2002 A preclinical study has been added to the Cancer pharmacodynamics section
  • 03 Aug 1999 Preclinical development for Cancer in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top